UNLABELLED: Low levels of high-density lipoprotein (HDL)-cholesterol represent an independent cardiovascular risk factor and, besides reduced physical activity, mechanisms leading to decreased HDL-cholesterol levels are not known. We aimed to test the hypothesis, that adiponectin provides a missing link between type 2 diabetes and low levels of HDL-cholesterol, independent from common metabolic risk factors. 523 patients with type 2 diabetes were investigated for adiponectin serum levels and parameters of lipid metabolism. Even after correction for age, gender, BMI and fasting insulin concentration, serum levels of adiponectin were highly significant (P<0.0001) and positively (regression analysis: r=0.86) associated with HDL-cholesterol levels in type 2 diabetes. CONCLUSION: adiponectin seems to predict HDL-cholesterol levels in patients with diabetes mellitus type 2. Low levels of adiponectin are associated with low levels of HDL-cholesterol independently from common metabolic risk factors and therefore represent an independent cardiovascular risk factor in type 2 diabetes. Thus, adiponectin is a potentially new drug target in the treatment of dyslipidaemia.
UNLABELLED: Low levels of high-density lipoprotein (HDL)-cholesterol represent an independent cardiovascular risk factor and, besides reduced physical activity, mechanisms leading to decreased HDL-cholesterol levels are not known. We aimed to test the hypothesis, that adiponectin provides a missing link between type 2 diabetes and low levels of HDL-cholesterol, independent from common metabolic risk factors. 523 patients with type 2 diabetes were investigated for adiponectin serum levels and parameters of lipid metabolism. Even after correction for age, gender, BMI and fasting insulin concentration, serum levels of adiponectin were highly significant (P<0.0001) and positively (regression analysis: r=0.86) associated with HDL-cholesterol levels in type 2 diabetes. CONCLUSION:adiponectin seems to predict HDL-cholesterol levels in patients with diabetes mellitus type 2. Low levels of adiponectin are associated with low levels of HDL-cholesterol independently from common metabolic risk factors and therefore represent an independent cardiovascular risk factor in type 2 diabetes. Thus, adiponectin is a potentially new drug target in the treatment of dyslipidaemia.
Authors: Narinder Bansal; Simon G Anderson; Avni Vyas; Isla Gemmell; Valentine Charlton-Menys; John Oldroyd; Philip Pemberton; Paul N Durrington; Peter E Clayton; J Kennedy Cruickshank Journal: J Clin Endocrinol Metab Date: 2011-06-01 Impact factor: 5.958
Authors: Anna V Goropashnaya; Johanna Herron; Mary Sexton; Peter J Havel; Kimber L Stanhope; Rosemarie Plaetke; Gerald V Mohatt; Bert B Boyer Journal: Metabolism Date: 2009-01 Impact factor: 8.694
Authors: Yajing Wang; Ling Tao; Yuexin Yuan; Wayne Bond Lau; Rong Li; Bernard L Lopez; Theodore A Christopher; Rong Tian; Xin-Liang Ma Journal: Am J Physiol Endocrinol Metab Date: 2009-05-26 Impact factor: 4.310
Authors: A Galkine; V Dzenkeviciute; V Sapoka; V Urbanavicius; Z Petrulioniene; G Brimas; A Laucevicius Journal: Acta Endocrinol (Buchar) Date: 2018 Oct-Dec Impact factor: 0.877
Authors: Krasimira Aleksandrova; Mazda Jenab; H Bas Bueno-de-Mesquita; Veronika Fedirko; Rudolf Kaaks; Annekatrin Lukanova; Fränzel J B van Duijnhoven; Eugene Jansen; Sabina Rinaldi; Isabelle Romieu; Pietro Ferrari; Neil Murphy; Marc J Gunter; Elio Riboli; Sabine Westhpal; Kim Overvad; Anne Tjønneland; Jytte Halkjær; Marie-Christine Boutron-Ruault; Laure Dossus; Antoine Racine; Antonia Trichopoulou; Christina Bamia; Philippos Orfanos; Claudia Agnoli; Domenico Palli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Petra H Peeters; Eric J Duell; Esther Molina-Montes; J Ramón Quirós; Miren Dorronsoro; Maria-Dolores Chirlaque; Aurelio Barricarte; Ingrid Ljuslinder; Richard Palmqvist; Ruth C Travis; Kay-Tee Khaw; Nicholas Wareham; Tobias Pischon; Heiner Boeing Journal: Eur J Epidemiol Date: 2014-05-04 Impact factor: 8.082